This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

The health care sector was relatively flat Thursday, as investors weighed an array of regulatory and clinical trial updates from companies.

BSD Medical (BSM) said Thursday that the Food and Drug Administration completed a pre-approval audit -- which included a five-day onsite inspection of its manufacturing process -- of its BSD-2000 hyperthermia system.

The company said the FDA didn't provide any written inspectional deficiencies, but it didn't allude to when it expects an approval decision. Shares added 51 cents, or 9.4%, to $5.96.

But ZymoGenetics (ZGEN) fell Thursday after announcing after the prior bell that the FDA review of its rThrombin blood clotting product would take an additional three months. The FDA needs the extra time to review additional data on a manufacturing facility. Shares were down $1.30, or 9.8%, at $11.98.

Other companies got a slight bump out of initiating or reporting data from mid-stage trials. CollaGenex Pharmaceuticals (CGPI) said a phase II dose-finding study achieved its primary endpoint and showed a statistically significant dose-response relationship of COL-118, a topical treatment for Erythema, a bright redness of the skin which is associated with certain dermatological conditions. Shares rose 18 cents, or 1.5%, to $12.18.

Regeneron Pharmaceuticals (REGN - Get Report) said Thursday that it initiated two double-blind, placebo-controlled phase III trials evaluating the safety and efficacy of aflibercept, which it's developing with Sanofi-Aventis, in combinations with standard chemotherapy regimens in patients with prostate cancer and nonsmall cell lung cancer.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CGPI $0.01 457.14%
AZN $34.25 0.91%
NVS $86.46 0.07%
MRK $53.86 0.71%
REGN $563.52 -0.70%


Chart of I:DJI
DOW 17,839.28 +27.09 0.15%
S&P 500 2,090.68 +1.54 0.07%
NASDAQ 5,119.2530 +16.4450 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs